830 results on '"Edelman, Martin J."'
Search Results
2. S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
3. “Cancer’s a demon”: a qualitative study of fear and multilevel factors contributing to cancer treatment delays
4. Targeted Therapies in Non-small Cell Lung Cancer
5. American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy
6. Appropriate Use Criteria (AUC) for Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Executive Summary of the American Radium Society's Systematic Review and Guidelines
7. Benchmarks for Academic Oncology Faculty.
8. Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP)
9. SWOG S1400C (NCT02154490)—A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration–Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
10. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer
11. American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer
12. American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non–Small Cell Lung Cancer
13. Targeted Therapies in Non-small Cell Lung Cancer
14. American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020
15. American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC
16. The Underappreciated Role of the Humoral Immune System and B Cells in Tumorigenesis and Cancer Therapeutics: A Review
17. Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic
18. Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non–small-cell Lung Cancer Treated With Curative Intent
19. “Cancer’s a demon”: a qualitative study of fear and multilevel factors contributing to cancer treatment delays
20. Hope-related goal cognitions and daily experiences of fatigue, pain, and functional concern among lung cancer patients
21. Lymph Node Size Predicts for Asymptomatic Brain Metastases in Patients With Non–small-cell Lung Cancer at Diagnosis
22. 50 Years of progress in the systemic therapy of non-small cell lung cancer.
23. Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing
24. Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622)
25. Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced, Non-Small Cell Lung Cancer
26. Chemotherapy Outcomes by Histologic Subtypes of Non-Small-Cell Lung Cancer: Analysis of the Southwest Oncology Group Database for Antimicrotubule-Platinum Therapy
27. Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
28. Development of a Multilevel Model to Identify Patients at Risk for Delay in Starting Cancer Treatment
29. Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non–Small Cell Lung Cancer: NRG Oncology RTOG 0839
30. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance)
31. American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma
32. Abstract 3310: Extracellular vesicles budding from stromal macrophages in the blood of metastatic non-small cell lung cancer patients correlates with poor survival
33. Abstract 1797: Impact of estrogen depletion using an aromatase inhibitor (AI) on EGFR-mutated non-small cell lung cancer (NSCLC) in a murine model
34. Supplementary Figure Legend from Anti-HDGF Targets Cancer and Cancer Stromal Stem Cells Resistant to Chemotherapy
35. Figures S1-S6 and Tables S1-S2 from Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy
36. Supplementary Figure 1 from Anti-HDGF Targets Cancer and Cancer Stromal Stem Cells Resistant to Chemotherapy
37. Supplementary Figures S1-S3 from Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias
38. Supplementary Figure 2 from Anti-HDGF Targets Cancer and Cancer Stromal Stem Cells Resistant to Chemotherapy
39. Supplementary Figure 1 from KML001 Cytotoxic Activity Is Associated with Its Binding to Telomeric Sequences and Telomere Erosion in Prostate Cancer Cells
40. Synthesis, anticancer activity, and SAR analyses of compounds containing the 5:7-fused 4,6,8-triaminoimidazo[4,5-e][1,3]diazepine ring system
41. Differential Gene Expression in Erlotinib-Treated Fibroblasts
42. Receptor Tyrosine Kinase EphA5 Is a Functional Molecular Target in Human Lung Cancer
43. Monitoring PD-L1 Expression on Circulating Tumor–Associated Cells in Recurrent Metastatic Non–Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy
44. Novel Targeted Agents and Radiopharmaceuticals in Lung Cancer
45. GP88 (progranulin): a novel tissue and circulating biomarker for non–small cell lung carcinoma
46. Daily Diary Study of Hope, Stigma, and Functioning in Lung Cancer Patients
47. Validation of Disability Status, a Claims-based Measure of Functional Status for Cancer Treatment and Outcomes Studies
48. Prognostic Factors for Small-Cell Lung Cancer
49. Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors
50. Abstract 2696: Catechol estrogen profiles of patients with EGFR- and ALK-positive non-small cell lung cancer (NSCLC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.